J.Jill Reports Steep Q1 Profit Decline, Sales Drop 6%, and Reaffirms Weak FY26 Outlook
Summary
J.Jill, Inc. announced Q1 FY26 results showing a 60% drop in net income and a 6.0% decline in net sales, alongside a negative outlook for Q2 and reaffirmed weak full-year guidance.
Key Events
-
Q1 FY26 Financial Performance Declines
Net sales decreased 6.0% to $144.4 million, comparable sales fell 8.7%, and net income dropped 60% to $4.7 million ($0.31 diluted EPS) compared to Q1 FY25. Adjusted EBITDA also declined significantly to $16.7 million from $27.3 million.
-
Gross Margin Impacted by Tariffs
Gross margin decreased to 68.3% from 71.8% in Q1 FY25, with approximately $4.7 million in incremental net tariff costs incurred during the quarter.
-
Negative Q2 FY26 Outlook
The company expects Q2 FY26 net sales to decline 1% to 3% and comparable sales to decline 2% to 4%, with gross margin expected to decrease by approximately 100 basis points due to tariffs.
-
Full-Year FY26 Outlook Reaffirmed
J.Jill reaffirmed its full-year outlook for net sales (flat to down 2%), comparable sales (down 1% to 3%), gross margin (down ~50 basis points), and Adjusted EBITDA ($70 million to $75 million), indicating continued challenges.
Analysis
J.Jill, Inc. reported a significant deterioration in its first-quarter financial performance, with net income falling by 60% and net sales declining by 6.0%. This continues the negative trend seen in the previous fiscal year. The company also provided a weak outlook for Q2 FY26, projecting further sales and comparable sales declines, and reaffirmed its already subdued full-year guidance. While the company maintained its dividend and executed a small share repurchase, these actions are overshadowed by the substantial operational and profitability challenges.
At the time of this filing, JILL was trading at $13.57 on NYSE in the Manufacturing sector, with a market capitalization of approximately $197.4M. The 52-week trading range was $10.41 to $18.80. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.